The company's product pipeline includes Sarconeos (BIO101), a first-in-class drug candidate for the treatment of sarcopenic obesity. The company develops drug candidates based on SARCOB and MACULIA technological platforms. As a clinical-stage biotech with limited market cap, Biophytis faces significant execution risk but operates in the high-value age-related disease therapeutics space.
Cyborg Score Rationale
Biophytis has differentiated assets in an important therapeutic area (age-related diseases) and has demonstrated clinical progress with Sarconeos. However, the company faces significant challenges: micromarket capitalization of €3.08m, delisting from NASDAQ in 2024 with transition to OTC markets, and limited public disclosure of recent clinical progress or financials. Binary clinical trial outcomes represent high execution risk.
Top Insights
Market cap of €3.08m as of June 2026 indicates severe capital constraints and limited runway for clinical development
NASDAQ delisting in 2024 reflects trading volume challenges and limited investor liquidity, now trading on LSE and Euronext Growth Paris
Lead program Sarconeos (BIO101) targets sarcopenic obesity, a condition with significant unmet medical need and aging population tailwinds
Dual therapeutic platform approach (SARCOB and MACULIA) provides pipeline depth but requires sustained capital availability
Named Competitors
Senolytic therapies — Cellular senescence targeting for age-related disease
GLP-1 derivative programs — Metabolic disease and aging-related conditions